Latest News-RemeGen Co., Ltd Mediaroom_Page

RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing

The biotech company continues to offer hope to systemic lupus erythematosus ( SLE) patients globally...

2024-05-10 16:26 3145

RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome

YANTAI, China, April 3, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" ...

2024-04-03 11:14 2596

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024

YANTAI, China, March 11, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" ...

2024-03-11 10:36 2382

World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap

YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or...

2024-02-02 21:30 2970

RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

YANTAI, China, Jan. 12, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK...

2024-01-12 18:17 2550

RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

YANTAI, China, Dec. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" ...

2023-12-28 15:45 2845

RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients

YANTAI, China, Dec. 18, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" ...

2023-12-18 20:56 2237

RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO)

YANTAI, China, Nov. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" ...

2023-11-28 09:48 2698

RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology

YANTAI, China, Nov. 15, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen"...

2023-11-15 16:35 2396

Remegen's Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis

YANTAI, China, Sept. 27, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen...

2023-09-27 09:30 3897

RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal

YANTAI, China, July 25, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen"...

2023-07-25 16:00 2282

RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhi...

2023-07-10 10:24 2860

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" ...

2023-06-05 21:26 3348

RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name

The "B" marker is removed from the Company's stock short name YANTAI, China, June 5, 2023 /PRNewswi...

2023-06-05 21:17 4237

RemeGen Celebrates World Intellectual Property Day 2023

YANTAI, China, April 26, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen...

2023-04-26 10:00 3359

On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy

YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen"...

2023-02-28 09:16 3546

RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen"...

2022-12-13 12:30 2839

RemeGen's Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines

YANTAI, China, Nov. 17, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.H...

2022-11-17 08:00 3695

RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients

YANTAI, China, Nov.1, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK,...

2022-11-01 12:12 2949

RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis

YANTAI, China, Oct. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.H...

2022-10-13 08:00 3899